We are investigating multiple aspects of non-coding RNA biology, with a particular focus on their roles in tumorigenesis and in mammalian development. Our approaches combine the use of genetically engineered mouse models, RNAi cell-based and in vivo screenings, high throughput genomic methods, and biochemistry. Here is a brief summary of some projects currently ongoing in our lab:
We have previously generated conditional and constitutive loss of function alleles for three related miRNA clusters in the mouse (Ventura et al., Cell 2008). These clusters are miR-17~92, miR-106b~25 and miR-106a~363. MiR-17~92 is also known as oncomir-1 because of its oncogenic properties in humans and mice. Our initial characterization of these null alleles in the mouse has revealed a critical role of miR-17~92 in controlling B cell survival and B cell development, as well as in regulating lung and heart development. Experiments performed on compound mutant animals for miR-17~92 and miR-106b~25 (one of its two paralogs) also suggest that these two miRNA clusters strongly synergizes in regulating early embryonic development.
By using spatially and temporally regulated Cre-expressing mice in combination with the conditional miR-17~92 allele, we are investigating the functions of this cluster in specific tissues and developmental stages. By employing a combination of gene targeting and in vitro experiments we are attempting to identify the functions of individual members of each miRNA clusters.
We have recently reported that a subset of patients affected by Feingold Syndrome -a rare autosomal dominant syndrome characterized by short stature, skeletal defects, learning disabilities and gastro-intestinal defects- harbor hemizygous germline deletions of the entire miR-17~92 cluster (De Pontual et al., Nature Genetics 2011). The role of miR-17~92 in the pathogenesis of this condition is confirmed by the fact that miR-17~92+/- mice display many of the key developmental defects observed in humans affected by Feingold Syndrome. We are currently investigating the molecular mechanisms through which reduced miR-17~92 dosage affects skeletal development and patterning.
We have recently demonstrated that miR-19a and miR-19b, two miRNAs encoded by the miR-17~92 cluster, are necessary and sufficient to confer oncogenic potential in the context of a mouse model of B cell lymphomas (Mu et al., G&D 2009).
To investigate the molecular mechanisms of miR-19 function and to determine its role in tumor progression, we have generated mice carrying selective targeted deletion of miR-19a and miR-19b. The characterization of these animals is providing important information regarding the roles of these two miRNAs in mammalian development and their contribution to a variety of mouse model of human cancers.
Three miRNAs (miR-34a, miR-34b and miR-34c) have been shown to be transcriptional targets of the p53 tumor suppressor protein and have been suggested to act as tumor-suppressor themselves. To investigate their biology, we have recently reported the generation of mice carrying targeted deletion of all three members of the miR-34 family (TKO mice). The characterization of these mice has indicates the miR-34 is not essential for the tumor-suppressive function of p53 and suggest the existence of additional, p53-independent, functions for this important miRNA family (Concepcion et al., PlOS Genetics 2012). We are currently investigating both the p53-dependent and p53-independent functions of miR-34 by using HITS-CLIP, RNAi screens and in vivo methods.
We have recently launched an effort to identify long-intergenic non-coding RNAs that possess oncogenic or tumor suppressor properties. To achieve this goal we are combining mouse models of human cancers, human tumor samples, RNAseq and RNAi-based screenings. The function of lincRNAs identified using this approach will be further examined by generating gain- and loss-of-function alleles in the mouse.
Identifying and functionally validating miRNA targets remains one of the main obstacles to fully understand the functions of miRNAs in biological processes. We are developing a novel method to identify bona fide miRNA-targets from whole tissues or from specific cell populations within a tissue. By combining the information gained through this approach with novel genome-editing technologies such as Talens, we hope to define a general strategy for the identification and in vivo validation of miRNA targets.